Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis / 国际儿科学杂志

ABSTRACT

Juvenile idiopathic arthritis (JIA)is one of the most common chronic rheumatic diseases in childhood.Systemic juvenile idiopathic arthritis(SJIA) is a subtype of JIA,which may be different from other subtypes.As shown in studies,interleukin-6 (IL-6),IL-18,IFN-γ,may instead of TNF-α,play an important role in SJIA.Traditional biological agents such as TNF antagonists have limited effect in the patients with SJIA.Tocilizumab(TCZ),a humanized anti-IL-6 receptor monoclonal antibody,inhibits the binding of IL-6 with transmembrane IL-6R or soluble IL-6R,blocking the IL-6 mediated inflammation and joint destruction.This article reviews the efficacy and safety of TCZ in patients with SJIA.